Image

Japan-based Takeda Pharmaceutical has announced the termination of orteronel (TAK-700) development for prostate cancer in Japan, the US and Europe.

The company has voluntarily decided to end the development programme for orteronel following the results of two Phase III clinical trials in metastatic, castration resistant prostate cancer (mCRPC) patients.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Last month, Takeda reported data from the pivotal Phase III trial, ELM-PC4, in men with mCRPC who had not received chemotherapy.

The double-blind, randomised Phase III trial showed that orteronel plus prednisone improved radiographic progression free survival compared with prednisone alone, one of the study’s two primary endpoints, but did not show a statistically significant improvement in the study’s second primary endpoint of overall survival.

"The pre-specified interim analysis indicated that orteronel plus prednisone would likely not meet the primary endpoint of improved overall survival when compared with the control arm."

In July 2013, Takeda announced that it has unblinded the ELM-PC 5 Phase III study of orteronel plus prednisone compared with placebo, plus prednisone in patients with mCRPC that had progressed during or following chemotherapy.

Takeda has unblinded the ELM-PC 5 Phase III study based on the recommendation of the Independent Data Monitoring Committee.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The pre-specified interim analysis indicated that orteronel plus prednisone would likely not meet the primary endpoint of improved overall survival when compared with the control arm.

The interim analysis did show an advantage for orteronel plus prednisone for the secondary endpoint, radiographic progression-free survival over the control arm. In addition, there were no safety concerns.

Orteronel is an investigational oral, non-steroidal, selective inhibitor of 17,20-lyase, a key enzyme in the production of steroidal hormones.

Image: Takeda Midosuji Building, headquarters of Takeda Pharmaceutical in Osaka, Japan. Photo: courtesy of J o.

Pharmaceutical Technology Excellence Awards - Nominations Closed

Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Awarded the 2025 Pharmaceutical Technology Excellence Award for Business Expansion in Integrated Manufacturing, Upperton Pharma Solutions is rapidly expanding its UK GMP and sterile manufacturing footprint. Find out how Upperton’s integrated CDMO model helps pharma companies move from early development to clinical and niche commercial supply with fewer handovers and faster timelines.

Discover the Impact